ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

ISA Pharmaceuticals will move to BioPartner 5

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer